On March 12, Dr. Ana Muntañola spoke as a speaker at a conference on the optimization of Bruton's tyrosine kinase inhibitors (BTK) conceived with the idea of raising awareness of new alternatives for the treatment of leukemia chronic lymphatic (LLC). It was held at the Gallery Hotel in Barcelona and counted with the participation of 3 speakers from other hospitals.
News
Dr. Muntañola participates in a conference on chronic lymphatic leukemia
Under the title "Inhibition of BTK: from theory to practice", Dr. Muntañola's conference focused on 4 real clinical cases of patients with CLL who treat HUMT. In this regard, he explained the alternatives for treatment that currently exist in the LLC in the first line and, according to each case, was developing the procedure to choose the best therapeutic option based on bibliographic data from recent publications and in the last presentations in the American Congress. of Hematology held last December in Atlanta (ASH Meeting).
In conclusion, Dr. Muntañola explained that, depending on the cytogenetic biological variables of poor prognosis, age and comorbidities of each patient, a treatment of chemo-immunotherapy or one of the new inhibitory drugs of the BCR will be better (= Recipient from cell B).